A Bachelor's Thesis by Kaj Kowalski
Vrije Universiteit Amsterdam
Supervisor: Dr. Pieter Koolwijk (Amsterdam UMC)
This thesis presents a systematic review investigating the effectiveness and safety of anti-angiogenic therapies for preventing Age-Related Macular Degeneration (AMD), a leading cause of vision loss in older adults. The research focuses on how these treatments impact visual outcomes and reduce treatment burden for patients.
Age-Related Macular Degeneration (AMD) is an eye condition that affects the macula, the central part of the retina responsible for sharp, detailed vision. It's the leading cause of severe vision loss in people over 50, particularly affecting those of European descent. AMD can significantly impact quality of life by making it difficult to read, drive, or recognize faces.
This study specifically examines anti-angiogenic therapies - treatments that work by blocking the formation of abnormal blood vessels in the eye. These blood vessels can leak and cause damage to the retina, leading to vision loss. The most common target of these therapies is VEGF (Vascular Endothelial Growth Factor), a protein that promotes blood vessel growth.
- How effective are anti-angiogenic therapies in preventing AMD progression?
- What are the safety profiles of different treatment approaches?
- How do various dosing schedules compare in terms of effectiveness and patient burden?
- What innovative combination therapies show promise for AMD treatment?
This systematic review analyzed 10 carefully selected studies including:
- Randomized controlled trials
- Prospective clinical studies
- Research from major medical databases (PubMed, ScienceDirect, Google Scholar)
All studies met strict inclusion criteria focusing on the efficacy and safety of anti-angiogenic treatments for AMD prevention.
- Treat-and-Extend (T&E) dosing schedules are as effective as traditional monthly treatments
- Significantly reduce the frequency of clinic visits and injections
- Offer a more personalized, patient-centered approach to care
- Maintain visual improvements while reducing treatment burden
- Innovative combination treatments show promising results
- Demonstrate marked improvements in both structural eye health and visual function
- Represent a potential future direction for optimizing treatment effectiveness
- Consistently low incidence of adverse effects across different dosing schedules
- High safety margins provide confidence in long-term treatment approaches
- Support the potential for improved patient well-being alongside clinical effectiveness
The findings of this research have important implications for:
- Patients: Fewer clinic visits and treatments while maintaining effectiveness
- Healthcare Providers: Evidence-based guidance for treatment planning
- Healthcare Systems: Potential reduction in treatment costs and resource utilization
- Future Research: Direction for developing next-generation AMD therapies
This systematic review contributes to the growing body of evidence supporting personalized medicine approaches in ophthalmology. By demonstrating that less frequent dosing can be equally effective, this research supports treatment strategies that prioritize both clinical outcomes and patient quality of life.
The work also highlights the promise of combination therapies, potentially opening new avenues for more effective AMD prevention and treatment strategies.
Kaj Kowalski is a bachelor's student at Vrije Universiteit Amsterdam, conducting this research under the supervision of Dr. Pieter Koolwijk at Amsterdam UMC. This thesis represents the culmination of undergraduate studies with a focus on medical research and ophthalmology.
For academic or research inquiries about this work, please contact: k.j.kowalski@student.vu.nl